Aegis Wealth Management LLC Takes $348,000 Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Key Points

• Aegis Wealth Management LLC has acquired a new stake in Dyne Therapeutics, purchasing 33,228 shares valued at approximately $348,000.
• Insider CEO John Cox has increased his ownership by 70.33%, acquiring 100,000 shares at an average price of $9.11 each, totaling $911,000.
• Dyne Therapeutics reported a quarterly EPS of (0.97), surpassing analyst expectations of (0.99), while its current price target consensus stands at $38.13.

Aegis Wealth Management LLC bought a new position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the 1st quarter, according to its most recent disclosure with the SEC. The firm bought 33,228 shares of the company's stock, valued at approximately $348,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. GF Fund Management CO. LTD. bought a new position in Dyne Therapeutics during the 4th quarter valued at about $50,000. Arizona State Retirement System raised its stake in Dyne Therapeutics by 9.2% during the 1st quarter. Arizona State Retirement System now owns 17,501 shares of the company's stock valued at $183,000 after buying an additional 1,481 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Dyne Therapeutics by 22.2% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 19,247 shares of the company's stock worth $201,000 after purchasing an additional 3,496 shares during the period. Summit Investment Advisors Inc. grew its position in Dyne Therapeutics by 9.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company's stock valued at $203,000 after buying an additional 721 shares during the period. Finally, Neo Ivy Capital Management purchased a new stake in Dyne Therapeutics during the fourth quarter valued at approximately $205,000. Hedge funds and other institutional investors own 96.68% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. HC Wainwright cut their price target on Dyne Therapeutics from $46.00 to $38.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Royal Bank Of Canada cut their target price on shares of Dyne Therapeutics from $25.00 to $23.00 and set an "outperform" rating for the company in a research note on Tuesday. Evercore ISI reissued an "outperform" rating on shares of Dyne Therapeutics in a report on Friday, July 11th. Robert W. Baird cut their price objective on Dyne Therapeutics from $46.00 to $32.00 and set an "outperform" rating for the company in a research report on Wednesday, June 18th. Finally, Raymond James Financial restated an "outperform" rating and issued a $31.00 price target (down previously from $37.00) on shares of Dyne Therapeutics in a research report on Tuesday. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $36.25.

Insider Activity at Dyne Therapeutics

In other news, CEO John Cox bought 100,000 shares of the firm's stock in a transaction that occurred on Monday, July 14th. The stock was bought at an average price of $9.11 per share, with a total value of $911,000.00. Following the completion of the transaction, the chief executive officer directly owned 242,179 shares of the company's stock, valued at approximately $2,206,250.69. The trade was a 70.33% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 14.14% of the stock is currently owned by company insiders.

Dyne Therapeutics Trading Up 2.0%

Shares of NASDAQ:DYN traded up $0.20 during trading hours on Friday, hitting $10.05. The company's stock had a trading volume of 2,751,418 shares, compared to its average volume of 2,750,633. The firm's fifty day moving average price is $10.75 and its 200 day moving average price is $11.52. Dyne Therapeutics, Inc. has a 52 week low of $6.36 and a 52 week high of $47.45. The company has a current ratio of 16.83, a quick ratio of 20.35 and a debt-to-equity ratio of 0.17.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its quarterly earnings data on Monday, July 28th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.99) by $0.02. On average, sell-side analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.